BYDUREON BCISE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BYDUREON BCISE (BYDUREON BCISE).
BYDUREON BCISE (exenatide extended-release) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and promoting satiety.
| Metabolism | Exenatide is primarily degraded by proteolytic cleavage; not significantly metabolized by cytochrome P450 enzymes. Renal excretion of intact peptide and metabolites. |
| Excretion | Excreted primarily via renal degradation; no significant biliary or fecal excretion. Approximately 70% of the dose is eliminated as intact exenatide via glomerular filtration and proteolytic catabolism. |
| Half-life | Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration, but the extended-release formulation provides prolonged exposure over 2 weeks via continuous release from microspheres. |
| Protein binding | 93% bound to albumin and other plasma proteins. |
| Volume of Distribution | Volume of distribution is approximately 28 L (0.4 L/kg), indicating limited extravascular distribution and consistent with minimal tissue binding. |
| Bioavailability | Absolute bioavailability after subcutaneous administration is approximately 100%, as the drug is fully absorbed from the injection site. |
| Onset of Action | Onset of glucose-lowering effect occurs within 2 hours after the first dose, with peak concentrations reached at 6-7 weeks due to the microsphere degradation profile. |
| Duration of Action | Duration of action is approximately 7 days per injection, allowing once-weekly dosing. Sustained therapeutic concentrations persist for up to 14 days after a single dose. |
Subcutaneous injection, 2 mg once weekly.
| Dosage form | SUSPENSION, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for eGFR >=30 mL/min/1.73 m2. Not recommended for use with eGFR <30 mL/min/1.73 m2 or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh A, B, C). |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established in patients <18 years. |
| Geriatric use | No dose adjustment required based on age alone. Consider renal function due to age-related decline; use caution in patients with eGFR <30 mL/min/1.73 m2. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BYDUREON BCISE (BYDUREON BCISE).
| Breastfeeding | Exenatide is excreted in rat milk at low concentrations; no human data available. The M/P ratio is unknown. Due to potential for infant hypoglycemia and lack of safety data, breastfeeding is not recommended during exenatide therapy. |
| Teratogenic Risk | Exenatide is an FDA Pregnancy Category C drug. In pregnant women, data are limited. Animal studies showed embryo-fetal toxicity (reduced fetal growth, skeletal abnormalities) at doses similar to human exposure. During first trimester, fetal exposure may occur via placental transfer. Second and third trimester risks include potential for maternal hypoglycemia (due to insulin secretagogue effect) and unknown effects on fetal pancreatic development. Exenatide is not recommended during pregnancy; insulin is preferred. |
■ FDA Black Box Warning
None
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma","Multiple endocrine neoplasia syndrome type 2 (MEN-2)","Severe hypersensitivity to exenatide or any product components"]
| Precautions | ["Risk of acute pancreatitis, including fatal hemorrhagic or necrotizing pancreatitis","Risk of hypoglycemia when used with insulin or insulin secretagogues","Renal impairment: acute renal failure reported, especially in patients with pre-existing renal disease","Gastrointestinal adverse reactions: nausea, vomiting, diarrhea","Thyroid C-cell tumors: increased risk of medullary thyroid carcinoma in animal studies","Hypersensitivity reactions including anaphylaxis and angioedema","Caution in patients with gastroparesis or severe gastrointestinal disease"] |
| Food/Dietary | No specific food interactions; BYDUREON BCISE may be administered without regard to meals. However, due to delayed gastric emptying, monitor for altered absorption of oral medications. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and HbA1c. Assess for signs of hypoglycemia, especially during pregnancy due to altered insulin sensitivity. Consider fetal growth scans if poor glycemic control. No specific fetal monitoring required beyond standard prenatal care. |
| Fertility Effects | Exenatide has no known direct effect on fertility in humans. In animal studies, exenatide cycles did not impair fertility. In patients with type 2 diabetes, improved glycemic control may restore ovulation in women with menstrual irregularities. |
| Clinical Pearls | BYDUREON BCISE (exenatide extended-release) is a GLP-1 receptor agonist administered once weekly. Do not use in patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. For patients with gastroparesis, consider alternative therapy due to delayed gastric emptying. Do not adjust dose based on age or mild/moderate renal impairment. Monitor for pancreatitis, renal function, and thyroid C-cell tumors (contraindicated in MEN 2 or medullary thyroid carcinoma history). Given in combination with metformin, sulfonylurea, or basal insulin; reduce sulfonylurea or insulin dose to minimize hypoglycemia risk. Anaphylaxis and angioedema have been reported; instruct patients to report allergic symptoms. |
| Patient Advice | Administer once every 7 days (same day each week) with or without food. · Inject subcutaneously in abdomen, thigh, or upper arm; rotate sites. · Do not use if suspension is discolored or contains particles; resuspend by rolling vial gently. · Seek immediate medical attention for symptoms of pancreatitis (severe abdominal pain, persistent vomiting). · Report symptoms of thyroid tumors: neck mass, difficulty swallowing, hoarseness. · Do not initiate during pregnancy; use effective contraception. · If a dose is missed, administer as soon as noticed if within 3 days; if >3 days, skip and resume next scheduled dose. |